Zhongchao Inc. (ZCMD) 株式分析
ヘルスケアZhongchao Inc.
$1.45
+$0.02 (+1.40%)
最終更新日: 2026年5月26日
株価推移
価格データがありません
分析
企業概要
Zhongchao Inc. operates within the healthcare sector, specifically focusing on health information services, where it delivers healthcare information, education, and training services to professionals under its MDMOOC brand in the People's Republic of China. The company generates revenue through two distinct business segments: MDMOOC services and the sales of patented drugs, with operations also extending to patient management services. As of the latest reporting period, the firm holds a market capitalization of $7.42 million and reported annual revenue of $11.37 million. Although specific employee count data is not publicly disclosed in the current dataset, the combination of these valuation and revenue figures positions Zhongchao Inc. as a small-cap entity with a relatively modest scale within the broader health information services industry. The current market capitalization suggests that the market assigns a limited valuation multiple to the company's revenue stream, indicating a niche operational footprint rather than a dominant market leader.
財務健全性
The company reported revenue of $11.37 million over the trailing twelve months, yet this generated a net income of -$6,310,153, revealing a significant negative gap that highlights a highly inefficient cost structure where expenses substantially exceed operational earnings. Further analysis of the EBITDA figure, which stands at -$5,901,042, indicates that even before interest and taxes, the core business operations are generating negative cash earnings, reflecting high operating costs or significant investment write-downs. Free cash flow for the period was -$1,112,632, demonstrating that the company is burning cash rather than generating liquidity, which severely limits its financial flexibility to fund organic growth or weather economic downturns without external capital injections. The company maintains a gross margin of 45.0%, suggesting that its cost of goods sold is controlled effectively relative to sales, but this is counterbalanced by an operating margin of -92.0% and a profit margin of -55.5%, which collectively indicate that general and administrative expenses are disproportionately high relative to revenue. In terms of leverage, Zhongchao Inc. holds $13.92 million in cash against only $26,083 in debt, resulting in a debt-to-equity ratio of 0.12, which suggests a conservative balance sheet structure that is not currently leveraged. This liquidity position is reinforced by a current ratio of 11.11, a metric that signifies the company possesses ample short-term assets to cover its short-term liabilities many times over. However, the return metrics tell a different story regarding management effectiveness, with a return on equity of -24.9% and a return on assets of -15.5%, indicating that the management team has failed to generate positive returns on the capital invested in the business.
バリュエーション評価
The trailing P/E ratio and forward P/E ratio are both listed as N/A due to the company's negative earnings, which prevents the use of traditional earnings-based valuation multiples and implies that the market cannot value the stock based on current profitability expectations. The price-to-book ratio stands at 0.30, indicating that the market is valuing the company at a significant discount to its book value, suggesting that investors perceive the assets on the balance sheet as potentially impaired or that future earnings potential is severely limited. Alternative valuation metrics provide further insight, with a price-to-sales ratio of 0.65 and an EV/EBITDA of 0.42, both of which reflect a very low valuation relative to sales and enterprise value, often seen in distressed or turnaround situations. The stock has exhibited significant volatility within its trading range, with a 52-week high of $12.18 and a 52-week low of $1.44, though the specific current price relative to this range is not explicitly provided in the dataset. The beta value is listed as N/A, meaning there is insufficient data to determine the stock's price volatility relative to the broader market movements.
Growth & Income
Revenue growth year-over-year has declined by 23.2%, while earnings growth is N/A given the negative net income, indicating that the company is shrinking in terms of top-line sales and is unable to demonstrate a path to profitability. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a capital allocation strategy where all earnings are theoretically available for reinvestment rather than distribution to shareholders. The absence of a dividend payout ratio means the company is not distributing any cash flow to investors, reinforcing the profile of a firm that relies entirely on operational cash generation or equity financing for funding. Overall, the growth and income profile is characterized by negative revenue expansion and a complete lack of income generation, presenting a challenging environment for capital preservation.
同業他社比較
Zhongchao Inc. (ZCMD) は医療情報サービス業界で事業を展開しています。時価総額による最も近い同業他社との比較は以下の通りです:
| 企業名 | ティッカー | 時価総額 | PER |
|---|---|---|---|
| Zhongchao Inc. | ZCMD | $5.59M | N/A |
| Veeva Systems Inc. | VEEV | $25.87B | 29.1 |
| BrightSpring Health Services, Inc. | BTSG | $11.70B | 78.3 |
| Tempus AI, Inc. | TEM | $8.38B | N/A |
医療情報サービス業界の平均PERは57.5倍です。Zhongchao Inc.のPERはN/Aです。
この分析はAIによって生成されたものであり、情報提供のみを目的としています。投資アドバイスではありません。データは遅延または不正確な場合があります。投資判断を行う前に、必ずご自身で調査を行い、資格を持つファイナンシャルアドバイザーにご相談ください。
関連する医療情報サービス銘柄
Veeva Systems Inc.
$25.87B
BTSGBrightSpring Health Services, Inc.
$11.70B
TEMTempus AI, Inc.
$8.38B
HQYHealthEquity, Inc.
$7.31B
HNGEHinge Health, Inc.
$4.10B
WAYWaystar Holding Corp.
$3.78B
ヘルスケアの人気銘柄
Eli Lilly and Company
$949.47B
JNJJohnson & Johnson
$554.09B
ABBVAbbVie Inc.
$376.54B
UNHUnitedHealth Group Incorporated
$342.24B
MRKMerck & Co., Inc.
$302.33B
Zhongchao Inc.について
Zhongchao Inc. provides healthcare information, education, and training services to healthcare professionals under their MDMOOC brand in the People's Republic of China. It operates through two segments, MDMOOC services, and Sales of Patented Drugs. The company offers patient management services in the tumor and rare diseases field, internet healthcare services, and pharmaceutical services, and operates an online information platform. It also provides online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes on popular medical topics, interactive case studies, academic conferences and workshops, continuing education courses, and articles and short videos with educational healthcare content. The company offers its services through its MDMOOC online platform, such as the MDMOOC mobile app, MOOC Medical WeChat subscription account, and MDMOOC website, and patient management services through an IT system under the Zhongxun brand, WeChat mini program, and Zhongxin Health WeChat mini program. It serves pharmaceutical enterprises and non-profit organizations, including medical associations, medical institutions, medical journals, medical foundations, and hospitals, as well as healthcare professionals, nurses, and doctors. Zhongchao Inc. was founded in 2012 and is headquartered in Shanghai, China.
企業説明は英語で表示されています。
ウェブサイトを見る →